Recombinant adenoviral vectors (rAds) are lead vaccine candidates for protection against a variety of pathogens, including Ebola, HIV, tuberculosis, and malaria, due to their ability to potently induce T cell immunity in humans. However, the ability to induce protective cellular immunity varies among rAds. Here, we assessed the mechanisms that control the potency of CD8 T cell responses in murine models following vaccination with human-, chimpanzee-, and simian-derived rAds encoding SIV-Gag antigen (Ag). After rAd vaccination, we quantified Ag expression and performed expression profiling of innate immune response genes in the draining lymph node. Human-derived rAd5 and chimpanzee-derived chAd3 were the most potent rAds and induced high and persistent Ag expression with low innate gene activation, while less potent rAds induced less Ag expression and robustly induced innate immunity genes that were primarily associated with IFN signaling. Abrogation of type I IFN or stimulator of IFN genes (STING) signaling increased Ag expression and accelerated CD8 T cell response kinetics but did not alter memory responses or protection. These findings reveal that the magnitude of rAd-induced memory CD8 T cell immune responses correlates with Ag expression but is independent of IFN and STING and provide criteria for optimizing protective CD8 T cell immunity with rAd vaccines.
Kylie M. Quinn, Daniel E. Zak, Andreia Costa, Ayako Yamamoto, Kathrin Kastenmuller, Brenna J. Hill, Geoffrey M. Lynn, Patricia A. Darrah, Ross W.B. Lindsay, Lingshu Wang, Cheng Cheng, Alfredo Nicosia, Antonella Folgori, Stefano Colloca, Riccardo Cortese, Emma Gostick, David A. Price, Jason G.D. Gall, Mario Roederer, Alan Aderem, Robert A. Seder
Title and authors | Publication | Year |
---|---|---|
Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection
O Flynn, K Dillane, JS Lanza, JM Marshall, J Jin, SE Silk, SJ Draper, AC Moore |
Human vaccines | 2021 |
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
LJ Kerstetter, S Buckley, CM Bliss, L Coughlan |
Frontiers in immunology | 2021 |
Codon Usage and Adenovirus Fitness: Implications for Vaccine Development
J Giménez-Roig, E Núñez-Manchón, R Alemany, E Villanueva, C Fillat |
Frontiers in microbiology | 2021 |
MAIT cell activation augments adenovirus vector vaccine immunogenicity
NM Provine, A Amini, LC Garner, AJ Spencer, C Dold, C Hutchings, LS Reyes, ME FitzPatrick, S Chinnakannan, B Oguti, M Raymond, M Ulaszewska, F Troise, H Sharpe, SB Morgan, TS Hinks, T Lambe, S Capone, A Folgori, E Barnes, CS Rollier, AJ Pollard, P Klenerman |
Science | 2021 |
Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression
J Guerrero-Rodríguez, A Cárdenas-Vargas, G Gutierrez-Silerio, A Sobrevilla-Navarro, B Bastidas-Ramírez, L Hernández-Ortega, C Gurrola-Díaz, L Gasca-Lozano, J Armendáriz-Borunda, A Salazar-Montes |
Molecular Biotechnology | 2021 |
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
MJ Sklar, S Maiolatesi, N Patterson, M Sedegah, K Limbach, N Teneza-Mora, I Chuang, KM Hollis-Perry, JG Banania, I Guzman, H Ganeshan, S Reyes, MR Hollingdale, M Wong, A Lindstrom, A Reyes, Y Alcorta, L Garver, K Bankard, A Belmonte, M Belmonte, J Huang, K Gowda, S Inoue, R Velasco, E Bergmann-Leitner, J Hutter, T Lee, N Adams, S Chaudhury, D Hunt, C Tamminga, E Berrie, D Bellamy, M Bittaye, K Ewer, C Diggs, LA Soisson, A Lawrie, A Hill, TL Richie, E Villasante, JE Epstein, CA Duplessis, SR Walsh |
PloS one | 2021 |
Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity
S Sanchez, N Palacio, T Dangi, T Ciucci, P Penaloza-MacMaster |
Science Immunology | 2021 |
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
S Capone, A Raggioli, M Gentile, S Battella, A Lahm, A Sommella, AM Contino, RA Urbanowicz, R Scala, F Barra, A Leuzzi, E Lilli, G Miselli, A Noto, M Ferraiuolo, F Talotta, T Tsoleridis, C Castilletti, G Matusali, F Colavita, D Lapa, S Meschi, M Capobianchi, M Soriani, A Folgori, JK Ball, S Colloca, A Vitelli |
Molecular Therapy | 2021 |
Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
A Elkashif, M Alhashimi, E Sayedahmed, S Sambhara, S Mittal |
IBMS BoneKEy | 2021 |
A New Look at Vaccine Strategies Against PPRV Focused on Adenoviral Candidates
J Rojas, N Sevilla, V Martín |
Frontiers in Veterinary Science | 2021 |
Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines
S Farhang-Sardroodi, C Korosec, S Gholami, M Craig, I Moyles, M Ghaemi, H Ooi, J Heffernan |
Human vaccines | 2021 |
Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses
J Powers, N Haese, M Denton, T Ando, C Kreklywich, K Bonin, C Streblow, N Kreklywich, P Smith, R Broeckel, V DeFilippis, T Morrison, M Heise, D Streblow, R Wang |
PLoS neglected tropical diseases | 2021 |
Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity
Sanchez S, Palacio N, Dangi T, Ciucci T, Penaloza-MacMaster P |
2021 |